Safety and efficacy of etrumadenant-based treatment in patients with metastatic castration-resistant prostate cancer: results from a phase 1b/2 study

Background Metastatic castration-resistant prostate cancer (mCRPC) remains incurable, with limited durable response to standard treatments. Preclinical data suggest that combining adenosine pathway blockade with immunotherapy and/or chemotherapy may activate and sustain antitumor immunity in prostate cancer. Etrumadenant is an oral, small-molecule, selective dual A 2a /A 2b receptor antagonist designed to inhibit adenosine-mediated immunosuppression. Methods The open-label phase 1b/2 ARC-6 (NCT04381832) study evaluated etrumadenant-based treatment combinations in males with mCRPC that progressed while receiving a novel hormonal agent. Patients were assigned to arms based on prior anticancer therapy (eg, taxane or abiraterone exposure) and received etrumadenant with zimberelimab, enzalutamide, docetaxel, sacituzumab govitecan, or quemliclustat or received docetaxel monotherapy. The primary endpoint was composite objective response rate (cORR), defined as the proportion of patients achieving a serum prostate-specific antigen (PSA) response and/or a radiographic response. Secondary endpoints included PSA response rate, radiographic response rate, and disease control rate. Results Between June 2020 and August 2024, 173 patients were treated. Most patients were aged ≥65 years (mean age across treatment arms, 69–74 years). The median (range) treatment duration across arms ranged from 11 (9–23) to 36 (9–67) weeks. In patients who were taxane-naive, cORR ranged from 25% in the etrumadenant and sacituzumab govitecan treatment arm to 55% in the etrumadenant, zimberelimab, and docetaxel treatment arm; response rates were numerically highest with docetaxel-containing combinations, particularly in stage 2. Across all treatment arms, among patients who were taxane-experienced, cORR was ≤14%; among patients who were abiraterone-experienced and taxane-naive, cORR was 21%. Serious treatment-emergent adverse events (TEAEs) occurred in 13–57% of patients. Most TEAEs were grade 1–2. Grade ≥3 TEAEs related to etrumadenant occurred in 6–57% of patients. Conclusions Etrumadenant-based treatments with zimberelimab and standard-of-care agents demonstrated a manageable safety profile and antitumor activity among a subset of patients with mCRPC.

Authors

Publication Details

Journal
Prostate Cancer and Prostatic Diseases
Published
2026-11-19
DOI
https://doi.org/10.1038/s41391-026-01172-x
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Safety and efficacy of etrumadenant-based treatment in patients with metastatic castration-resistant prostate cancer: results from a phase 1b/2 study

Michael Anthony Carducci, Sumit Kumar Subudhi, Subhransu Prusty, Sandy T Liu et al.
Prostate Cancer and Prostatic Diseases
Prostate Cancer Treatment and Research
article

Safety and efficacy of etrumadenant-based treatment in patients with metastatic castration-resistant prostate cancer: results from a phase 1b/2 study

Michael Anthony Carducci, Sumit Kumar Subudhi, Subhransu Prusty, Sandy T Liu, Lawrence H. Fong, David R. Wise, Arvind Chaudhry, Tingting Zhao, Maureen O’Connell
article en

Abstract

Background Metastatic castration-resistant prostate cancer (mCRPC) remains incurable, with limited durable response to standard treatments. Preclinical data suggest that combining adenosine pathway blockade with immunotherapy and/or chemotherapy may activate and sustain antitumor immunity in prostate cancer. Etrumadenant is an oral, small-molecule, selective dual A 2a /A 2b receptor antagonist designed to inhibit adenosine-mediated immunosuppression. Methods The open-label phase 1b/2 ARC-6 (NCT04381832) study evaluated etrumadenant-based treatment combinations in males with mCRPC that progressed while receiving a novel hormonal agent. Patients were assigned to arms based on prior anticancer therapy (eg, taxane or abiraterone exposure) and received etrumadenant with zimberelimab, enzalutamide, docetaxel, sacituzumab govitecan, or quemliclustat or received docetaxel monotherapy. The primary endpoint was composite objective response rate (cORR), defined as the proportion of patients achieving a serum prostate-specific antigen (PSA) response and/or a radiographic response. Secondary endpoints included PSA response rate, radiographic response rate, and disease control rate. Results Between June 2020 and August 2024, 173 patients were treated. Most patients were aged ≥65 years (mean age across treatment arms, 69–74 years). The median (range) treatment duration across arms ranged from 11 (9–23) to 36 (9–67) weeks. In patients who were taxane-naive, cORR ranged from 25% in the etrumadenant and sacituzumab govitecan treatment arm to 55% in the etrumadenant, zimberelimab, and docetaxel treatment arm; response rates were numerically highest with docetaxel-containing combinations, particularly in stage 2. Across all treatment arms, among patients who were taxane-experienced, cORR was ≤14%; among patients who were abiraterone-experienced and taxane-naive, cORR was 21%. Serious treatment-emergent adverse events (TEAEs) occurred in 13–57% of patients. Most TEAEs were grade 1–2. Grade ≥3 TEAEs related to etrumadenant occurred in 6–57% of patients. Conclusions Etrumadenant-based treatments with zimberelimab and standard-of-care agents demonstrated a manageable safety profile and antitumor activity among a subset of patients with mCRPC.

Prostate Cancer and Prostatic Diseases
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon